Dashboard
Manage Tickers

AZNASTRAZENECA PLC

Nasdaq astrazeneca.com


$ 80.02 $ 1.03 (1.3 %)    

Tuesday, 04-Jun-2024 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ 1.24 (0.27 %)
DIA $ 398.57 $ 1.27 (0.33 %)
SPY $ 530.36 $ 0.59 (0.11 %)
TLT $ 91.26 $ 1.07 (1.17 %)
GLD $ 225.37 $ -1.95 (-0.9 %)
$ 80.02
$ 79.50
$ 80.01 x 200
$ 80.08 x 100
$ 79.26 - $ 80.07
$ 59.55 - $ 80.07
3,959,262
na
124.99B
$ 0.56
$ 7.31
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

heres-how-much-you-would-have-made-owning-astrazeneca-stock-in-the-last-5-years
Here's How Much You Would Have Made Owning...
06/04/2024 17:30:18

Core News & Articles
Reported Earlier, Daiichi Sankyo And Astra...
06/03/2024 06:49:46

DESTINY-Breast06 results show Daiichi Sankyo and AstraZeneca's ENHERTU is the first HER2 directed medicine and antibody d...

astrazeneca-announced-tagrisso-reduced-the-risk-of-disease-progression-or-death-by-84-in-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer-vs-placebo-in-laura-phase-iii-trial
AstraZeneca Announced Tagrisso Reduced The...
06/02/2024 18:25:18

Positive results from the LAURA Phase III trial showed AstraZeneca's Tagrisso (osimertinib) demonstrated a statistically si...

astrazeneca-announced-imfinzi-reduces-death-risk-by-27-vs-placebo-in-global-phase-iii-trial-in-limited-stage-small-cell-lung-cancer-with-57-survival-rate-at-three-years
AstraZeneca Announced Imfinzi Reduces Deat...
06/02/2024 14:16:21

Results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI®(durvalumab) ​demonstrated statistically significant and...

Core News & Articles
Fusion Pharmaceuticals Obtains Final Court...
05/31/2024 20:08:50

astrazeneca-ceo-says-no-need-for-further-mergers-and-acquisitions-inflation-reduction-act-could-impact-top-line-by-500m-pascal-soriot-aims-to-nearly-double-sales-by-2030-no-plans-to-retire
AstraZeneca CEO Says No Need For Further M...
05/31/2024 13:27:24

- Dow Jones Citing Interview

argus-research-maintains-buy-on-astrazeneca-raises-price-target-to-85
Argus Research Maintains Buy on AstraZenec...
05/30/2024 18:02:12

Argus Research analyst Jasper Hellweg maintains AstraZeneca (NASDAQ:AZN) with a Buy and raises the price target from $80 to ...

goldman-sachs-initiates-coverage-on-astrazeneca-with-buy-rating-announces-price-target-of-97
Goldman Sachs Initiates Coverage On AstraZ...
05/30/2024 10:46:05

Goldman Sachs analyst Rajan Sharma initiates coverage on AstraZeneca (NASDAQ:AZN) with a Buy rating and announces Price Targ...

Core News & Articles
Fusion Pharmaceuticals Shareholders Approv...
05/29/2024 20:10:23

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjuga...

amgen-secures-fda-nod-for-rare-disease-treatment-biosimilar-based-on-astrazenecas-drug
Amgen Secures FDA Nod For Rare-Disease Tre...
05/29/2024 16:51:29

The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare d...

why-is-astrazeneca-stock-trading-lower-on-tuesday
Why Is AstraZeneca Stock Trading Lower On ...
05/28/2024 18:32:38

AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patient...

astrazeneca-merck-gsk-struck-record-441b-licensing-deals-with-chinese-drugmakers-in-2023-report
AstraZeneca, Merck, GSK Struck Record $44....
05/27/2024 11:12:58

Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers.

biden-administration-urges-supreme-court-review-in-terrorism-funding-lawsuit-against-pharma-companies
Biden Administration Urges Supreme Court R...
05/23/2024 18:00:16

U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medi...

tango-therapeutics-shuts-early-stage-cancer-study-due-to-liver-toxicity
Tango Therapeutics Shuts Early-Stage Cance...
05/23/2024 16:53:11

Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now...

Core News & Articles
Ionis Pharmaceuticals Will Present New Sub...
05/23/2024 11:21:41

WAINUA was approved by the FDA in December 2023 for the treatment of the polyneuropathy of hereditary transthyretin-mediated am...

reported-earlier-nona-biosciences-enters-global-license-agreement-with-astrazeneca-for-monoclonal-antibody-development
Reported Earlier, Nona Biosciences Enters ...
05/23/2024 07:13:53

heres-how-much-you-would-have-made-owning-astrazeneca-stock-in-the-last-5-years
Here's How Much You Would Have Made Owning...
05/22/2024 15:01:08

Core News & Articles
'Disease Experts Predict A Small Rise In C...
05/22/2024 14:59:46

https://www.nbcnews.com/now/video/disease-experts-predict-a-small-rise-in-covid-cases-this-summer-211393605953 Disease experts ...

astrazeneca-targets-ambitious-80b-in-total-revenue-by-2030-through-pipeline-expansion
AstraZeneca Targets Ambitious $80B In Tota...
05/21/2024 11:16:06

AstraZeneca aims to boost its revenue from $45.8 billion in 2023 to $80 billion by 2030. Key growth drivers include expanding o...

astrazeneca-aims-for-80b-revenue-by-2030-with-bold-plans-for-20-new-medicines-and-sustainable-growth
AstraZeneca Aims For $80B Revenue By 2030 ...
05/21/2024 06:13:44

Launch of 20 new medicines expected by 2030 Significant growth from existing oncology, biopharmaceuticals and rare disease p...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION